Codeine

Quick links to important sections

Codeine

Method of action: Antitussive Opioid

Treatment option: Cough

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Codeine

Quick Facts

Property Description
Active Ingredient Codeine (Methylmorphine)
Forms Tablet, Capsule, Oral Solution, Syrup
Pharmacological Class Opioid Analgesic, Antitussive
Common Use Pain relief, cough suppression
Origin Naturally occurring Alkaloid and Semi-synthetic

Codeine: An Opioid Analgesic and Antitussive

Codeine is an opioid analgesic and antitussive that functions as a Central Nervous System (CNS) Depressant, defining its primary role in medicine for managing pain and controlling coughs. The active ingredient, known chemically as methylmorphine, alters how the central nervous system processes pain signals. Codeine is included on the Model List of Essential Medicines for adults for general pain management in populations where its efficacy is clinically recognized.

This compound's classification also includes its distinct role as an antitussive, acting directly on the cough center in the brainstem to suppress the reflex. Pharmacological studies support the antitussive action of Codeine, confirming its ability to decrease the urge to cough. This dual function—modifying pain perception and reducing the reflex to cough—is fundamental to understanding the breadth of its therapeutic applications.

The Composition and Origin of Codeine

The active pharmaceutical ingredient, Codeine, is a naturally occurring phenanthrene alkaloid derived from the opium poppy plant (Papaver somniferum), although it is classified as semi-synthetic due to the required chemical refinement for manufacturing. The drug is intended for oral administration and is supplied in various dosage forms, including conventional tablets, capsules, oral solutions, and syrups. The availability of Codeine in liquid forms provides a suitable option for individuals experiencing difficulty swallowing.

Pharmacologically, Codeine is defined as a pro-drug because it must be metabolized by the liver into active morphine to achieve its primary analgesic effects. It is available both as a single-ingredient drug and frequently integrated into combination products alongside non-opioid pain relievers.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. NIH: Codeine - StatPearls Overview
  3. WHO Essential Medicines List: Codeine Monograph
  4. Codeine: MedlinePlus Drug Information

What side effects are possible with Codeine?

Possible Side Effects and Safety Information

The safety profile of codeine is defined by its action as an opioid analgesic and Central Nervous System (CNS) depressant, according to government regulatory documents (e.g., FDA and EMA). The documented adverse effects are categorized by frequency and the body system affected.


Common Adverse Reactions and Organ Systems

The most frequently reported adverse reactions listed in regulatory prescribing information involve the CNS and the gastrointestinal system. These are typically noted to occur during treatment initiation.

System-Organ Class Most Common Documented Effects
Nervous System Drowsiness, Sedation, Dizziness, Light-headedness
Gastrointestinal System Nausea, Vomiting, Constipation (often persistent)
Integumentary System Sweating, Pruritus (Itching)

Serious Risks and Regulatory Constraints

Official labeling emphasizes serious risks associated with codeine use:

  • Life-Threatening Respiratory Depression: This is the primary serious risk, with the highest potential for occurrence during the initiation of therapy or following a dose increase.
  • Opioid-Related Risks: These include the potential for Addiction, Abuse, and Misuse, as well as the risk of Neonatal Opioid Withdrawal Syndrome with prolonged use during pregnancy.
  • Fatal Overdose Risk: Ingestion of even a single dose, particularly by children, may be fatal.
  • Drug Interactions: Co-administration with other CNS depressants (e.g., benzodiazepines, alcohol) may result in profound sedation, coma, and death.

Population-Specific Contraindications

Codeine is contraindicated in several specific populations due to heightened safety concerns, as mandated by regulatory agencies:

  • Children: Contraindicated for all use in children younger than 12 years of age.
  • Ultra-Rapid Metabolizers: Contraindicated in individuals of any age who are known to be CYP2D6 ultra-rapid metabolizers due to the fatal risk of high morphine levels.
  • Post-Operative: Contraindicated in patients younger than 18 years following tonsillectomy or adenoidectomy.

Overdose and Emergency Response

The official regulatory profile for Codeine overdose is defined by its severe effects as an opioid Central Nervous System (CNS) depressant. Documented overdose manifestations involve a progression of CNS suppression beginning with extreme drowsiness and stupor, which can progress rapidly to coma and loss of consciousness. Other recognized clinical signs include miosis (pinpoint pupils), cold, and clammy skin.

The primary life-threatening outcome documented in prescribing information is respiratory depression—a severe reduction in breathing rate and depth. This condition can escalate to apnea (cessation of breathing), circulatory collapse, and ultimately, death. Because of these serious, acute risks, official labeling mandates that individuals seek immediate medical attention and contact emergency services for any suspected overdosage.

The documented emergency management procedure centers on the administration of the specific opioid antagonist, Naloxone, to reverse the profound respiratory effects. Supportive measures, such as maintaining adequate pulmonary ventilation and symptomatic care, are also required. Regulatory documents explicitly note heightened risks for certain populations; accidental ingestion of even a single dose by a child can be fatal. Furthermore, Codeine is contraindicated in children under 12 years due to the severe danger posed to ultra-rapid metabolizers.

Therapeutic Uses of Codeine

This medication is used in situations involving certain distressing symptoms, primarily for its analgesic and antitussive properties.

Codeine is commonly used to address symptoms related to physical discomfort and pain classified as mild to moderate in intensity. It is applied in scenarios where additional management of discomfort is required, such as following an injury or surgical procedure. The core indications where it is relevant include providing support for mild to moderate pain relief, moderating persistent and exhausting coughs, and assisting with symptomatic management for diarrhea.

This therapeutic use is relevant for managing symptoms that interfere with daily comfort, and generally contributes to easing the overall symptom load. The medication may assist with supporting functional stability and is commonly applied in clinical settings that involve acute or unstable symptom patterns, providing supportive relief when symptoms interfere with routine activities.

Supportive Relief for Symptoms

Quick Fact: Symptomatic Support for Pain Quick Fact: Symptomatic Support for Cough
Targets: Mild to moderate pain Targets: Persistent, nonproductive cough
Benefit: Helps address discomfort and functional strain Benefit: Supports rest and may help ease disruption

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Codeine's official regulatory profile defines eligibility based primarily on age, genetic risk, and underlying health status, strictly limiting its use to certain populations.

Contraindicated Populations

The medicine is contraindicated for use in all children younger than 12 years of age. This prohibition is extended to adolescents younger than 18 years following tonsillectomy or adenoidectomy. A critical non-eligibility rule applies to patients of any age who are known ultra-rapid metabolizers of the medicine, due to genetic variability that can lead to dangerously high levels of its active metabolite. Use is also strictly contraindicated for patients with significant respiratory depression, acute or severe bronchial asthma, or gastrointestinal obstruction such as paralytic ileus.

Restricted and Conditional Use

Regulatory agencies do not recommend Codeine for use in women who are breastfeeding due to the risk of serious adverse reactions in the infant. Prolonged use during pregnancy carries the documented risk of Neonatal Opioid Withdrawal Syndrome. Use is avoided in adolescents (12–18 years) with pre-existing risk factors like obstructive sleep apnea. Caution and close monitoring are required for older adults and patients with severe renal or hepatic impairment.

What should I know about interactions with other medicines?

Codeine Interactions with other medicines and products

Codeine's interaction profile is significantly influenced by its metabolism via the Cytochrome P450 (CYP) 2D6 enzyme and the risk of additive Central Nervous System (CNS) depression.

Contraindicated and High-Risk Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), or use within 14 days of stopping them, is contraindicated due to the risk of potentiating opioid effects. The use of codeine is also contraindicated in patients known to be CYP2D6 ultra-rapid metabolizers due to the increased risk of high morphine levels and severe respiratory depression. Benzodiazepines and other CNS depressants (e.g., alcohol, general anesthetics) present a serious risk of profound sedation, respiratory depression, coma, and death. If combination is necessary, close monitoring and dose reduction are required.

Pharmacokinetic Interactions

Drugs that inhibit CYP2D6 (e.g., quinidine) can reduce the conversion of codeine to the active metabolite morphine, potentially leading to a decrease in analgesic effectiveness. Conversely, inhibitors or inducers of CYP3A4 (e.g., certain antibiotics or anti-epileptics) may alter codeine plasma concentrations, requiring patient monitoring for signs of increased side effects or withdrawal symptoms.

Other Clinically Relevant Interactions

Concurrent use with serotonergic drugs (e.g., SSRIs, triptans) may result in Serotonin Syndrome, mandating careful observation during initiation and dose adjustments. Concomitant use with mixed agonist/antagonist or partial agonist opioid analgesics may reduce the analgesic effect of codeine or precipitate withdrawal symptoms.

Mechanism of Action

How Codeine Works: Mechanism of Action

Codeine functions as a prodrug that undergoes O-demethylation, primarily via the liver enzyme CYP2D6, to form its active metabolite, morphine. Morphine then acts as an agonist at the mu-opioid receptor (mu-OR), a G-protein coupled receptor, throughout the central nervous system (CNS).

Activation of mu-ORs inhibits neuronal excitability by coupling to inhibitory G-proteins, which decreases calcium ion influx and increases potassium ion efflux. This mechanism reduces neurotransmitter release and hyperpolarizes the neuron, resulting in the dampened transmission of pain signals in the spinal cord and supraspinal pathways.

Furthermore, mu-OR activation in the medulla oblongata depresses the cough reflex center, leading to a reduction in the excitability of the cough center. In the enteric nervous system, this mechanism slows the release of excitatory transmitters, resulting in a reduction of intestinal contractile activity (peristalsis).


Biological Constraint on Mechanistic Efficacy

The rate of metabolism by the CYP2D6 enzyme introduces a biological constraint on the amount of active metabolite generated. This enzymatic conversion rate determines the concentration of the active agonist available to modulate the targeted pathways.

Dosage and Administration Information

How to Use Codeine: Official Administration Guidelines

Codeine is primarily administered via the oral route as immediate-release tablets or oral solutions, defining its most common use pattern. The drug is taken according to a structured regimen that strictly controls dose, frequency, and duration.

Administration Scope

Instruction Detail
Dosing Schedule The standard adult dosage for pain relief ranges from 15 mg to 60 mg, with the maximum single dose not exceeding 60 mg. The maximum dose over a 24-hour period varies, reaching a maximum daily total between 240 mg and 360 mg depending on regional guidelines.
Frequency and Timing The drug is taken as needed (PRN), typically every 4 to 6 hours, ensuring the interval between doses is not less than 4 hours.
Duration Limit Treatment should utilize the lowest effective dosage for the shortest duration. For acute pain, the duration of use is often limited to a maximum of 3 days.

Procedural Administration Rules

Dosing is always individualized, starting at the lowest effective level. Oral forms may be taken with or just after food. When using liquid forms, a calibrated oral syringe or cup must be used for measurement, as household spoons are not accurate for ensuring the correct dose.

Age-Specific Rules

The medicine is contraindicated for all individuals younger than 12 years of age. Additionally, it is contraindicated in adolescents under 18 years old following tonsillectomy and/or adenoidectomy. Dose reductions are required for use in older adults and patients with hepatic or renal impairment. If the drug is used long-term and dependence is established, gradual tapering is necessary upon cessation.

Recent Clinical Evidence

Research evidence / Overview of studies for Codeine

Evidence Landscape for Mild to Moderate Acute Pain

Research exploring the evaluation of codeine for outcomes related to physical discomfort consists primarily of Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily involve adult populations who are experiencing acute pain, such as the discomfort that follows dental procedures or various surgical interventions. In these trials, researchers examined metrics like patient-reported outcomes describing perceived discomfort and the need for additional pain relief medication.

Much of the evidence base focuses on codeine administered as a combination product alongside non-opioid pain relievers. Studies reported how symptoms evolved in the observed populations over defined time intervals, typically focusing on short-term symptom changes. Findings were mixed and heterogeneous (varied) across different pain models and patient groups. The overall evidence quality for codeine in acute pain is often designated as Moderate to Low.

Evidence Base for Persistent, Nonproductive Cough

Codeine was studied for its role as an antitussive, applied in research contexts involving episodic or acute changes in cough patterns, often associated with upper respiratory tract infections. The evidence includes RCTs and Systematic Reviews that monitored outcomes such as objective cough frequency and subjective reports of cough severity.

Studies reported how symptoms evolved in the observed populations, but many systematic reviews noted that findings were mixed, and some trials reported no significant differences when comparing codeine to a placebo control. The research body for codeine's antitussive effect is often designated as having low certainty. Peer-reviewed scientific literature has noted that the existing data is inconsistent.

Summary of Evidence Quality and Research Uncertainty

Across all studied indications, research is primarily relevant in trials assessing short-term or episodic symptom patterns. The evidence level for most indications is broadly described as Low to Moderate. What is known is that follow-up durations were limited, and there remains a significant gap where long-term effects are not fully established. Furthermore, the frequent use of combination products complicates the interpretation of codeine's standalone effect. The research landscape confirms that data for pediatric groups remain insufficient for broad evaluations.

Key Studies & References

  1. Management of acute pain in adults: a review of the evidence
  2. Codeine: Drug Information (NIH MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Codeine (FAQ)

Q: What is the risk of dependency or addiction with short-term Codeine use?

A: Official warnings state that the risk of addiction, abuse, and misuse exists for all opioid pain relievers, including Codeine. Dependency can potentially develop even with repeated use over a relatively short time frame. Regulatory guidelines emphasize utilizing the lowest effective dose for the shortest possible duration to help mitigate these potential risks.

Q: Are there any dietary restrictions or foods to avoid while taking Codeine?

A: Regulatory information and product leaflets generally state that patients can eat and drink normally while taking Codeine, apart from the known interaction with alcohol. Unless a healthcare professional provides specific instructions, there are typically no major food or dietary restrictions noted.

Q: What happens if I accidentally miss a dose of Codeine?

A: If Codeine is being taken on an as-needed basis (PRN), official health information generally indicates that one should skip the missed dose and simply continue the regular dosing schedule as prescribed. It is advised not to take a double dose to compensate for the one that was missed.

Q: What research is available on the effectiveness of Codeine for chronic pain?

A: Codeine is officially indicated for the treatment of mild to moderately severe pain. The evidence base often focuses on short-term or acute pain, and studies on its long-term effects for chronic pain are limited. Official use is often characterized by the regulatory principle of utilizing the lowest effective dose for the shortest possible duration.

Q: Why do some people experience nausea when taking Codeine?

A: Nausea is a frequently reported side effect associated with Codeine use. This occurs because opioid medications, including Codeine and its active metabolite morphine, can cause nausea through their actions on the central nervous system and the gastrointestinal system.

Q: Does Codeine accumulate in the body with regular use?

A: When Codeine is administered regularly, such as every four hours, the concentrations of Codeine and its primary active metabolite, morphine, typically reach a steady-state concentration within about 48 hours. This means the amount of drug entering and leaving the body remains generally balanced.

Q: Can Codeine be taken on an empty stomach?

A: Official administration guidelines state that oral forms of Codeine may be taken with or immediately after food. While taking it on an empty stomach is not strictly prohibited, taking it with food is often suggested to help mitigate the likelihood of experiencing common gastrointestinal side effects like nausea.

Q: What is the function of Codeine in the body that helps with coughing?

A: Codeine works as an antitussive, meaning it suppresses coughs. It does this by acting to depress the cough reflex center located in the brainstem. This action reduces the excitability and the urgency of the urge to cough.

Q: Why is Codeine sometimes included in combination products with other drugs?

A: Codeine is often combined with non-opioid medications, such as acetaminophen or aspirin, to achieve enhanced pain relief (analgesia). It may also be integrated with other ingredients for use as a comprehensive cough and cold remedy.

Q: Why is Codeine sometimes less effective for some people than for others?

A: Variations in effectiveness are often linked to genetic factors related to how the body processes the drug. The liver enzyme CYP2D6 metabolizes Codeine into its active form, morphine. Some individuals are classified as 'poor metabolizers,' which results in lower active morphine levels and therefore reduced pain-relieving efficacy.

Q: Can Codeine interact with blood thinning medications?

A: Yes, regulatory information indicates that Codeine, particularly when combined with acetaminophen, has reported interactions with blood thinners such as warfarin. Regulatory warnings highlight the need for close medical monitoring and potential dose adjustments when these medications are used together.

Q: What are the common sleep disturbances or effects on sleep patterns reported with Codeine?

A: The most commonly reported central nervous system side effects are drowsiness and sedation. While these effects may naturally alter a person's sleep patterns, specific or detailed sleep disturbances are not always elaborated upon in standard regulatory safety summaries.

Q: Can Codeine interact with common medications for anxiety or sleep?

A: Official warnings caution that co-administration with other Central Nervous System (CNS) depressants, which includes many medicines for anxiety and sleep, carries serious risks. Combining these types of drugs can lead to profound sedation, severe respiratory depression, coma, and even death.

Q: What is the role of Codeine in a palliative care setting?

A: Codeine is recognized as an essential medicine on the World Health Organization (WHO) Model List for palliative care. It may be used for managing mild to moderate pain, as well as for its ability to help control symptoms like persistent cough.

Q: Are there specific patient groups for whom Codeine is not recommended due to genetic factors?

A: Yes, official safety labeling advises against the use of Codeine in individuals of any age who are known to be CYP2D6 ultra-rapid metabolizers. This genetic variability leads to the dangerously fast conversion of Codeine to morphine, creating a high and potentially fatal risk of adverse effects.

Q: Can Codeine interact with herbal supplements?

A: Official health guidance strongly notes the importance of disclosing to a healthcare professional all medications, including any herbal products and supplements that may be taken. Some supplements, like St. John's wort or tryptophan, have been reported to interact with Codeine.

Q: What is the difference between Codeine phosphate and Codeine sulfate?

A: Codeine phosphate and Codeine sulfate are different salt forms of the same active medicinal ingredient, Codeine. The salt form does not typically change the core function of the drug as an analgesic (pain reliever) or an antitussive (cough suppressant).

Q: Are there any studies comparing Codeine's pain relief to tramadol?

A: While regulatory bodies have issued safety communications acknowledging that both Codeine and tramadol are used to treat pain and carry similar risks in specific patient populations, direct, head-to-head comparisons of their efficacy are not routinely detailed in standard regulatory documents.

Q: Does Codeine lose its effectiveness over time if used regularly?

A: Yes, with repeated, regular use, a person may develop tolerance to Codeine. Tolerance is the body's diminished response to the drug, which means the medication may lose some of its original effectiveness in relieving pain.

Q: Does Codeine have an effect on blood pressure?

A: Official safety information indicates that Codeine use can sometimes be associated with low blood pressure, medically known as hypotension. Symptoms may include feelings of dizziness, light-headedness, or temporary blurred vision.

Q: What is the typical time frame for stopping Codeine without major side effects?

A: For individuals who have developed physical dependence, gradual tapering is necessary to minimize withdrawal symptoms. However, official regulatory information does not provide a single, universal time frame for safely stopping Codeine after short-term use; this procedure depends on individual factors and medical guidance.

How should Codeine be stored and disposed of?

Codeine must be stored according to regulatory requirements to maintain product stability and ensure safety as an opioid.

Official Storage Conditions

Requirement Specifics Based on Labeling
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C
Protection Keep in the original, tightly closed container; protect from excessive moisture and heat, and do not freeze
Child-Safety Must be stored in a secure, locked location and out of the sight and reach of children due to the risk of accidental overdose

Disposal Instructions

Disposal must follow specific regulatory protocols for controlled substances:

  1. The primary method for discarding unused or expired product is an authorized drug take-back program (e.g., pharmacy drop-off or mail-back).
  2. If take-back is unavailable, the product may be disposed of in household trash by mixing it with an undesirable substance (e.g., coffee grounds, dirt) and sealing it in a container.
  3. Certain immediate-release Codeine formulations may be on the FDA Flush List and should be flushed immediately if a take-back option is not available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Codeine found in:

A-Z Index: